 |
| Author | Post |
|---|
Admin
Administrator
| Joined: | Tue Apr 10th, 2007 |
| Location: | |
| Posts: | 457 |
| Status: |
Offline
|
| Mana: |  |
|
Posted: Tue May 12th, 2009 01:23 pm |
|
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30
NEW YORK, May 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) will hold a conference call on Thursday, May 14, 2009 at 8:30 a.m. EDT to discuss the first quarter 2009 financial results and a business outlook for the remainder of 2009. Michael P. Tarnok, Interim Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.
In order to participate in the conference call, please call 1-877-407-8289 (U.S.), 1-201-689-8341 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com/, for a period of 15 days after the call.
The press release announcing our financial results for this period will be posted on the Company's website, http://www.keryx.com/, prior to the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also actively engages in business development activities that include seeking strategic relationships for its product candidates and for the Company, as well as evaluating compounds and companies for in-licensing or acquisition. Keryx is headquartered in New York City.
KERYX CONTACT: Lauren Fischer Director Investor Relations Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965 E-mail:
DATASOURCE: Keryx Biopharmaceuticals, Inc.
CONTACT: Lauren Fischer Director, Investor Relations Keryx
Biopharmaceuticals, Inc. +1-212-531-5965,
Web Site: http://www.keryx.com/
|
Admin
Administrator
| Joined: | Tue Apr 10th, 2007 |
| Location: | |
| Posts: | 457 |
| Status: |
Offline
|
| Mana: | |
|
Posted: Thu May 7th, 2009 03:19 pm |
|
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the acquisition, development, and commercialization of pharmaceutical products for the treatment of diabetes and cancer. The company's endocrine/renal products include Sulonex, a Phase III and Phase IV clinical stage product for the treatment of diabetic nephropathy; and Zerenex, a Phase II clinical stage product for the treatment of Hyperphosphatemia in patients with end-stage renal disease. Its oncology products include KRX-0401, a Phase II clinical stage product for the treatment of multiple forms of cancer; KRX-0402, a Phase II clinical stage product for the treatment of brain cancer; KRX-0601, a Phase II clinical stage product for the treatment of multiple forms of cancer; and KRX-0404, a pre-clinical stage product for the treatment of multiple forms of cancer. The company also develops neurology products, including KRX-0501, a pre-clinical stage product for the treatment of neurological disorders. In addition, it offers AccuminTM, a patent protected, diagnostic for the direct measurement of total and intact urinary albumin. It has strategic alliances with Alfa Wassermann S.p.A.; Collaborative Study Group; AEterna Zentaris, Inc.; Panion & BF Biotech, Inc.; Kyowa Hakko Kogyo Co., Ltd.; and AusAm Biotechnologies, Inc. for the manufacture and commercialization of its products. Keryx Biopharmaceuticals was founded in 1998. It was formerly known as Paramount Pharmaceuticals, Inc. and changed its name to Lakaro Biopharmaceuticals, Inc. in 1999. Later, the company changed its name to Keryx Biopharmaceuticals, Inc. in 2000. Keryx Biopharmaceuticals is based in New York, New York
Keryx Webpage http://www.keryx.com
Trading .32
Corporate Headquarters
Keryx Biopharmaceuticals, Inc.
750 Lexington Ave. - 20th Floor
New York, NY 10022
Phone: 1-212-531-5965
Fax: 1-212-531-5961
Contact Emails
Investor Relations IR@keryx.com
Business Development BusDev@keryx.com
Clinical Trials ClinicalTrials@keryx.com
Employment Opportunities jobs@keryx.com
My Comments:
I think and this is my opinion why I bought this issue.
First: They have in their pipeline and clinical trials, 2 drugs in stage II.
Second: They brought on Mr. Tarnok for interim CEO and has most of his professional career spent with Pfizer..This could be a key factor for me and why I have a position, since it may bring in collaboration with Pfizer ..Of course this is my opinion.
Also, Mr. Tarnok acquired 100000 shares on April 29th...Based on Form-4 4/29/09.
As I have mentioned, I have a position and feel comfortable that we will start a run up..How far is anybody's guess, but I'm betting on Mr. Tarnok and Mr. Oliviero who has extensive knowledge with Securities and Exchange Commission rules and regulations and other corporate governance matters.
Reason why I say collaboration, is that Pfizer has limited pipeline and has pretty much exhausted their in-house research and must find small R&D Bio-companies to stay competitive..
With the current Phase II in progress, a collaboration seems to be the way until the clinical trials moves further into advance stages..
Most collaboration partnerships are results of the small R&D companies relying on shareholders and other sources of funding ( Equity Type Financial Instruments ) until further stages become evident, like stages II and III that show promise, will ultimately catch the eye of the large Pharma and is what I see here.
The collaboration seems more advantageous to us shareholders and would carry KERX through many ongoing clinical trials that costs millions.
On a later date, the licensee or marketing that only a large Pharma can execute, as well manufacturing would fit nicely.
Certainly the last two trading sessions something is definitely in the works.
There are 52 institutions that hold 26% of this issue.
Analyst consensus target 12 month $3 and in the last quarter 2009 rated this issue a buy.
Consensus target means just that, a estimate and should not be taken as a recommendation, as a analyst myself, I will put a target of .80 by years end.
I'm basing my target on an infusion of collaboration on financing and positive ongoing clinical trials moving forward.
I have not received compensation to recommend this issue.
This is still a speculative buy recommendation since the company did receive a delisting notice..However, I feel the company as stated above, is trying to make the right moves.
I own it and my average buy in was .32
Have a good day
Varok
Last edited on Thu May 7th, 2009 08:49 pm by Admin
|
Current time is 01:24 pm | |
|
|
|
|
